Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

Caroline Seymour
Published: Thursday, Jun 14, 2018

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD
At the 2018 ASCO Annual Meeting, data for the combinations of the anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab (Rituxan), and ibrutinib (Imbruvica) plus venetoclax (Venclexta), both showed practice-changing potential to transform the complex field of non-Hodgkin lymphoma (NHL).

The combination of 5F9 with rituximab demonstrated strong signals of activity and tolerability in patients with relapsed/refractory NHL. The initial phase Ib/II results revealed the efficacy of 5F9 in patients with rituximab-refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.1 Across all doses, the overall response rate (ORR) was 50%, with a complete remission (CR) rate of 36%.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication